Can CD10 be used as a diagnostic marker in thyroid pathology?

Area of Science:

• Oncology
• Immunohistochemistry
• Thyroid Pathology

Background:

• CD10, a zinc metalloproteinase, is expressed in various cell types and neoplasms.
• Previous studies suggested CD10's utility in differentiating benign and malignant thyroid lesions.
• Thyroid neoplasms present diagnostic challenges, necessitating reliable biomarkers.

Purpose of the Study:

• To evaluate the diagnostic utility of CD10 expression in various thyroid lesions.
• To assess CD10's effectiveness in distinguishing benign from malignant thyroid follicular lesions.
• To determine if CD10 expression correlates with specific thyroid carcinoma subtypes.

Main Methods:

• Immunohistochemical staining for CD10 was performed on 75 thyroid lesions (14 benign, 61 malignant) and adjacent normal thyroid tissue.
• Staining patterns were analyzed and compared across different benign and malignant thyroid entities.
• Statistical analysis was used to assess the significance of CD10 expression in various thyroid pathologies.

Main Results:

• CD10 was negative in normal thyroid tissue, adenomas, and minimally invasive follicular carcinoma.
• Significant CD10 positivity was observed in conventional papillary thyroid carcinoma (64.2%).
• Lower CD10 expression was noted in follicular variant papillary carcinomas (16.6%) and follicular adenomas (30%).

Conclusions:

• CD10 is not a reliable marker for classifying thyroid follicular lesions as benign or malignant.
• CD10 demonstrates strong positivity in conventional papillary thyroid carcinoma, suggesting its potential as a specific marker for this subtype.
• Further research is warranted to fully elucidate CD10's role in thyroid cancer diagnostics.